Capha Pharmaceuticals Inc.
FPSUF
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.29% | 15.22% | 9.20% | 13.73% | -5.88% |
| Depreciation & Amortization | -- | -- | -- | -100.00% | -100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.04% | 15.22% | 9.09% | 12.62% | -5.04% |
| Operating Income | 15.04% | -15.22% | -9.09% | -12.62% | 5.04% |
| Income Before Tax | 22.67% | -34.86% | 13.08% | -9.92% | 6.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.67% | -34.86% | 13.08% | -9.92% | 6.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.67% | -34.86% | 13.08% | -9.92% | 6.25% |
| EBIT | 15.04% | -15.22% | -9.09% | -12.62% | 5.04% |
| EBITDA | 14.29% | -15.22% | -9.20% | -13.73% | 5.88% |
| EPS Basic | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Normalized Basic EPS | 0.00% | 0.00% | 0.00% | 0.00% | 50.00% |
| EPS Diluted | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Normalized Diluted EPS | 0.00% | 0.00% | 0.00% | 0.00% | 50.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |